Drug intelligence / Profile preview

prasterone enanthate + estradiol valerate

Development stage
Phase 3
Lead developer
Bayer
Modality
Small Molecules
Administration
Intramuscular
01

Overview

This drug is a **combination injectable formulation** consisting of **estradiol valerate**, a synthetic estrogen, and **prasterone enanthate** (DHEA enanthate), a weak androgen, estrogen, and neurosteroid. It is used as **menopausal hormone therapy in women** to treat menopausal symptoms. Estradiol valerate acts as an estrogen receptor agonist, while prasterone enanthate serves as a long-acting prodrug of prasterone (DHEA), providing mild androgenic, estrogenic, and neurosteroid effects. The combination aims to relieve estrogen deficiency symptoms while also potentially providing psychotropic benefits without masculinizing effects at standard doses. Given via intramuscular injection, the medication is formulated in oil solution, typically administered every 4–6 weeks. It was first described in 1972, introduced for medical use in 1975, and is available in several countries in Europe, Latin America, and Egypt[1][2][3].

Brand names
Gynodian DepotBinodian DepotCidodian DepotKlimaxSupligol NF
Other names
estradiol valerate/prasterone enanthateEV/DHEA-EEV/PESH-70833-DSH70833-DSH 70833-D
02

Targets

ESR2 (ERβ)GABAA (Gamma-aminobutyric acid receptor)AR (Adrenergic receptors)ESR1 (ERα)

Beyond the preview

Go deeper on prasterone enanthate + estradiol valerate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prasterone enanthate + estradiol valerate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call